Temple University of the Commonwealth System of Higher Education Patent applications |
Patent application number | Title | Published |
20160115124 | SMALL MOLECULE RNASE INHIBITORS AND METHODS OF USE - Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection. | 04-28-2016 |
20160018403 | STABILIZED PEPTIDE FRAGMENTS FROM REDOXIN PROTEINS AS CANCER BIOMARKERS - An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject. | 01-21-2016 |
20160017301 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus. | 01-21-2016 |
20160016941 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. | 01-21-2016 |
20150283118 | SMALL MOLECULE RNASE INHIBITORS AND METHODS OF USE - Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. | 10-08-2015 |
20150140127 | METHOD FOR DETECTING INJURY TO THE BRAIN - Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain. | 05-21-2015 |
20150010901 | METHOD FOR DETECTING POLYOMAVIRUS REACTIVATION - The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease. | 01-08-2015 |
20140294843 | DIAGNOSIS AND TREATMENT OF COPD - Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD. | 10-02-2014 |
20140279316 | APPARATUS, METHOD, AND COMPUTER READABLE MEDIUM FOR DISPLAYING GENERAL LEDGER FUNDS IN A CHECKBOOK FORMAT - Apparatus, computer readable medium, and a method for interacting with a user on a computer for displaying grants, the method comprising displaying grants with an icon indicating a balance of the grant; and in response to a selection of one of the displayed grants comprising transactions by the user, displaying transactions of the selected grant in a row comprising a column for transactions that lower the balance, a column for transactions that raise the balance, and a column for the balance, and displaying an icon for the column for transactions that lowers the balance and an icon for the column for transactions that raises the balance. The method may comprise retrieving credits and debits and displaying in the column for transactions that lower the balance, credits and debits that lower the balance, and displaying in the column for transactions that raise the balance, credits and debits that raise the balance. | 09-18-2014 |
20140234827 | SSAT mRNA TRANSLATION REPRESSION AND ACTIVATION - The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase (“SSAT”), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation. | 08-21-2014 |
20140231352 | SILICA PARTICLES COATED WITH BETA-CYCLODEXTRIN FOR THE REMOVAL OF EMERGING CONTAMINANTS FROM WASTEWATER - Provided is a silica particle coated with β-cyclodextrin, wherein said cyclodextrin is attached to said silica particle via at least one crosslinking agent and/or at least one copolymer. Also provided are methods of removing contaminants from a flowing or stationary liquid phase comprising the step of contacting said liquid phase with the silica particle coated with β-cyclodextrin. | 08-21-2014 |
20140216116 | SIEVED COMPOST AND HYDROGEL-BASED METHOD AND COMPOSITION FOR SEED PRIMING - Provided is a method for seed priming comprising the steps of treating seed with a seed priming composition comprising sieved compost, hydrogel and water in a ratio of sieved compost:hydrogel:water of from about 5:1:4.75 to about 9:1:11 by weight in an amount sufficient to result in priming of the seed. In some embodiments, the seed is treated with from about 2 to about 39 grams of the seed priming composition per gram of seed. In preferred embodiments, the seed composition and the seed priming composition are free of soil or sand. In further preferred embodiments, the seed is blended with the seed priming composition at a temperature of about 5° C. to about 25° C. | 08-07-2014 |
20140186431 | COMBINED MESENCHYMAL STEM CELL TRANSPLANTATION AND TARGETED DELIVERY OF VEGF FOR TREATMENT OF MYOCARDIAL INFARCTION - Compositions and kits useful for the treatment of myocardial infarction comprise (i) P-selectin-targeted carriers (e.g., P-selectin-targeted liposomes, quantum dots or biodegradable nanoparticles) comprising VEGF and (ii) MSCs. | 07-03-2014 |
20140086941 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF - The present invention relates to compounds according to Formula I: | 03-27-2014 |
20140057833 | ADIPONECTIN RECEPTOR AGONISTS AND METHODS OF USE - Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided. | 02-27-2014 |
20140030735 | BIOMARKERS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring. | 01-30-2014 |
20140011206 | DETERMINATION OF OOCYTE QUALITY - A method for evaluating the quality of mammalian oocytes comprises determining the expression level of one or more of the genes ACPP, AQP11, CCDC126, CLU, CYP11 A1, CYP19A1, EGR3, FN1, FOSL2, GMNN, HRAS, HSD3B2, HS-D17B1, HSD11B2, HSDL1, IGF1, IGFBP4, IGFBP5, IRS1, KCNK3, KLF6, NEK6, SMAD7 or STC1 in a test sample derived from a cumulus cell or granulosa cell associated with the oocyte, and comparing the expression level of said at least one marker gene expression in the sample with the expression level in a control. Differential expression of the gene between the sample and the control is indicative of the quality of the oocyte. | 01-09-2014 |
20130321801 | FILAMENT-BASED STIMULATED RAMAN DETECTION - In apparatus and methods of Raman spectroscopy in air, a target region is excited by a laser pump pulse exceeding the critical power for self-focusing in air and having a duration after self-focusing of 15 fs or less. A laser probe pulse having a duration in the range of 200 fs to 100 ps and an energy of at least 20 μJ is directed at the excited target region. Stimulated Raman scattering from the interaction between the excited target region and the laser probe pulse is detected. The target region can be outside the spectrometer, with ambient air in between used for the self-focusing. | 12-05-2013 |
20130310421 | TREATMENT OF AMYLOID BETA AMYLOIDOSIS - Provided is a method for the treatment and/or prevention of an amyloid beta amyloidosis in a subject comprising the step of administering to the subject an effective amount of a 5-lipoxygenase-activating protein (FLAP) antagonist. In preferred embodiments, the FLAP antagonist is MK-591, or a pharmaceutically acceptable salt thereof. Also provided is a method for decreasing or preventing the deposition of beta amyloid in the brain of a subject comprising the step of administering to a subject an effective amount of a FLAP antagonist. In preferred embodiments, the FLAP antagonist is MK-591, or a pharmaceutically acceptable salt thereof. | 11-21-2013 |
20130237685 | LINEAR ASSEMBLIES, BRANCHED ASSEMBLIES, MACROCYCLES AND COVALENT BUNDLES OF FUNCTIONALIZED BIS-PEPTIDES - Provided is a macromolecule comprising two or more functionalized bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the functionalized bis-peptides are covalently attached to one or more functionalized bis-peptides to form linear strings of functionalized bis-peptides, macrocycles of functionalized bis-peptides, three-dimensional networks of functionalized bis-peptides, and combinations of any of these. Also provided is a macromolecule comprising two or more bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the bis-peptides comprise non-functionalized bis-peptides, functionalized bis-peptides or a combination of both functionalized and non-functionalized bis-peptides. In some embodiments, the bis-peptides are covalently attached to one or more bis-peptides to form linear strings of bis-peptides, macrocycles of bis-peptides, three-dimensional networks of bis-peptides, and combinations of any of these. | 09-12-2013 |
20130202752 | CHOCOLATE PRODUCTION METHOD AND APPARATUS - The present invention relates to a method and an apparatus for producing a chocolate product. The method includes delivering liquid chocolate having a viscosity through a pipe along a delivery path to a production station for producing the chocolate product. The liquid chocolate includes solid particles suspended within the liquid chocolate. The method changes the viscosity of the liquid chocolate by applying an electric field to the liquid chocolate in a direction along the delivery path of a strength and duration determined to aggregate the suspended solid particles into streamlined shapes extending along the direction of the delivery path. | 08-08-2013 |
20130196963 | TOPICAL STEROIDAL FORMULATIONS - The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome. | 08-01-2013 |
20130196959 | TOPICAL STEROIDAL FORMULATIONS - The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome. | 08-01-2013 |
20130183317 | G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 AS A CANCER BIOMARKER - A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed. | 07-18-2013 |
20130096335 | PROCESS FOR SYNTHESIS OF SILANE DIPEPTIDE ANALOGS - The invention provides a method of preparing silane dipeptide analogs, comprising the steps of treating a solution of a substituted 1,2-oxasilolane with lithium metal to form a solution of the dilithium salt of a substituted 3-hydroxypropylsilanol, and reacting the solution of the dilithium salt of the substituted 3-hydroxypropylsilanol with a substituted enamine. | 04-18-2013 |
20130070074 | APPARATUS AND METHOD FOR SURFACE AND SUBSURFACE TACTILE SENSATION IMAGING - A tactile sensor, computer readable medium, methods of using and manufacturing the tactile sensor, and methods and apparatuses for processing the information generated by the tactile sensor. The tactile sensor includes a planar optical waveguide comprised of a flexible and transparent layer; a light configured to direct light into the optical waveguide; a light sensor or an imager facing the optical waveguide and configured to generate signals from light scattered out of the optical waveguide; and a controller which may be configured to generate an image of the object and characteristics of the object. The waveguide may be configured so that some of the light directed into the optical waveguide is scattered out of the waveguide if the waveguide is deformed by being pressed against the object. A finite element and a neural network are used to estimate mechanical characteristics of the objects. | 03-21-2013 |
20120329828 | Cocaine Analogs and Methods of Preparation and Uses Thereof - The invention provides novel cocaine analogs. The invention also provides a method of preparing cocaine analogs with control over the substituents installed at the C-1, C-2, C-3, C-4 and N-8 positions of the tropane bicyclic scaffold. The invention further provides methods of providing anesthesia, blocking reuptake of a monoamine neurotransmitter, and treating depression, by administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the invention. | 12-27-2012 |
20120305773 | METHODS AND SYSTEMS FOR REMOTELY DETECTING HAZARDOUS MATERIALS USING ELECTROMAGNETIC ENERGY - Systems and methods for remotely detecting nuclear and non-nuclear materials such as chemical agents and gas-phase explosives are disclosed. Nuclear and non-nuclear materials may be detected by transmitting electromagnetic energy toward a remote target area, collecting scattered electromagnetic energy reflected from the remote target area, analyzing an absorption spectrum of the collected scattered electromagnetic energy, and detecting a presence of at least one nuclear or non-nuclear material in the remote target area based on the analyzed absorption spectrum. | 12-06-2012 |
20120269831 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to Formula (I), wherein n, A, R | 10-25-2012 |
20120219570 | G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 AS A CANCER BIOMARKER - A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed. | 08-30-2012 |
20120183555 | SERUM MARKERS ASSOCIATED WITH EARLY AND OTHER STAGES OF BREAST CANCER - Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers. | 07-19-2012 |
20120122987 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) - Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation. | 05-17-2012 |
20120108504 | LEPTIN AGONIST AND METHODS OF USE - Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance. | 05-03-2012 |
20120024044 | SYSTEMS AND METHODS FOR DETECTING CONCEALED NUCLEAR MATERIAL - Methods and systems for detecting nuclear material concealed within an enclosure are provided. An ionized air density is measured at one or more locations outside of the enclosure. The presence of the concealed nuclear material is detected, for each of the one or more locations, based on a characteristic of the measured ionized air density indicative of concealed nuclear materials. | 02-02-2012 |
20120021130 | METHOD FOR INHIBITING DECOMPOSITION OF METAL SULFIDE-CONTAINING MATERIAL - This invention provides methods of producing a crosslinked lipid coating on a metal sulfide-containing material using a chemical initiator. The crosslinked lipid coating attached to the surface of the material prevents dissolution or oxidation of the material. The methods may be useful to prevent oxidation and leaking of sulfide-containing material in the environment and may be used in the control of environmental pollution. | 01-26-2012 |
20120017467 | ORTHOTIC SHOE AND INSOLE ASSEMBLIES - An orthotic shoe sole assembly and an orthotic insole are disclosed herein. The orthotic shoe assembly includes a shoe sole having an exposed surface and at least one exposed cavity accessible via the exposed surface. The at least one exposed cavity includes a central region and a plurality of channels extending from the central region. A resilient member is removably positioned within the central region of the exposed cavity. The resilient member is configured to resiliently expand into at least one of the plurality of channels of the exposed cavity. The orthotic insole is removably positioned to selectively conceal the exposed cavity of the shoe sole and the resilient member. The orthotic insole includes a central axis member for supporting a foot along its central axis. | 01-26-2012 |
20110294698 | PROCESS FOR IDENTIFYING DRUGS FOR TREATING GASTROESOPHAGEAL REFLUX - Methods for identifying modulators of gastroesophageal smooth muscle relaxation include isolating various types of smooth muscle fibers from the stomach or esophagus and inducing the fibers to contract. The isolated and contracted fibers are used to screen test compounds for the compound's capacity to modulate relaxation of the smooth muscle fibers. In addition, newly identified unique nicotinic acetylcholine receptors are expressed in a cell, and used to screen test compounds for the compound's capacity to modulate the biological activity of the receptors. | 12-01-2011 |
20110288021 | ADMINISTRATION OF ANGIOCIDIN FOR THE TREATMENT OF CANCER - Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype. | 11-24-2011 |
20110274611 | PURIFICATION OF SINGLE WALLED CARBON NANOTUBES BY DYNAMIC ANNEALING - A method for removing impurities from carbon nanotubes is described. Impurities may be removed from the carbon nanotubes by exposing the carbon nanotubes to a temperature, and controlling the temperature such that the temperature is constantly increasing to remove at least a portion of the impurities from the carbon nanotubes. | 11-10-2011 |
20110251614 | LOCKING ROD FUSION DEVICE - A locking rod fusion device and method uses internal locking rods and screws that will lock together. In particular, the device allows the insertion of multiple locking rods in combination with a plate, which requires less dissection and disruption of soft tissues and vasculature. The device also provides a more stable internal construct for fusions that prevent non-unions, hardware failure and reoccurrence of deformities, such as Charcot foot. The device combines the strength of locking technology and the utility and ease of an internal rod system to provide a single stable construct in multiple planes as apposed to using multiple plates or screws separately. | 10-13-2011 |
20110184171 | ACYLATION OF HINDERED AMINES AND FUNCTIONALIZED BIS-PEPTIDES OBTAINED THEREBY - Functionalized bis-peptides as well as other amide-containing compounds are obtained by acylation of hindered amines. The functionalized bis-peptides are useful as shape-programmable nanostructures that are immune to denaturation and that contain arrays of functional groups having designed catalytic, protein-binding and/or sensor capabilities. | 07-28-2011 |
20110162646 | PROCESS FOR TRANSIENT AND STEADY STATE DELIVERY OF BIOLOGICAL AGENTS TO THE LUNG VIA BREATHABLE LIQUIDS - The present invention includes a transient method of delivering a biological agent in a breathable liquid to a lung of a patient. The present invention includes a steady state method of delivering a biological agent in a breathable liquid to a lung of a patient. The steps of both the transient delivery method and the steady state delivery method can be controlled by a servo-control unit. A supplementary biological agent delivery step can be performed in both the transient method of delivering a biological agent and the steady state method of delivering a biological agent. | 07-07-2011 |
20100321767 | METHODS AND DEVICES FOR GENERATION OF BROADBAND PULSED RADIATION - Methods and apparatus for non-collinear optical parametric ampliffication (NOPA) are provided. Broadband phase matching is achieved with a non-collinear geometry and a divergent signal seed to provide bandwidth gain. A chirp may be introduced into the pump pulse such that the white light seed is amplified in a broad spectral region. | 12-23-2010 |
20100305059 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA - Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: | 12-02-2010 |
20100291595 | BLOOD MONOCYTE CD163 EXPRESSION AS A BIOMARKER IN HIV-1 INFECTION AND NEUROAIDS - The invention provides a method for detecting CD163+/CD16+ cell population in peripheral blood mononuclear cells in a biological sample from a subject infected with HIV-1 which comprises contacting the biological sample with an anti-CD163 antibody, so that levels of CD163+/CD16+ peripheral blood mononuclear cells in the biological sample can be quantified. The method of the present invention is particularly useful for monitoring the course of HIV-1 infection and/or HIV Encephalopathy | 11-18-2010 |
20100284921 | TARGETED NANOPARTICLES FOR INTRACELLULAR CANCER THERAPY - This invention provides constructs comprising a targeting member immobilized on a detectable particulate, in which binding of the targeting member to a target structure on a surface of a cancer cell triggers internalization of the construct. Such constructs can be used to identify or monitor cancer cells in cell cultures or in a tissue. Such construct can also be used to kill or prevent growth of cancer cells in vivo. Also included in the invention are methods for killing or preventing growth of cancer cells in vivo. | 11-11-2010 |
20100204673 | OBESITY CONTROLLING METHOD - A method of controlling obesity by injecting bio-compatible bulking material into the pyloric sphincter area of the stomach. The injection of this material bulks the pyloric sphincter, retarding stomach emptying and producing a feeling of satiation in the patient. The method may be supplemental and augmented by inducing flacid paralysis of the stomach by injecting botulinum toxin into the muscle tissue of the antrum or fundus of the stomach. | 08-12-2010 |
20100136036 | UNCONVENTIONAL ANTIGEN TRANSLATED BY A NOVEL INTERNAL RIBOSOME ENTRY SITE ELICITS ANTITUMOR HUMORAL IMMUNE REACTIONS - The invention provides a novel antigen, MPD6, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′ untranslated region (3′UTR) of myotrophin mRNA. MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES mediated translation, but not myotrophin-MPD6 transcription, was significantly upregulated in response to IFN-α stimulation. These findings demonstrate that a novel IRES-mediated mechanism is responsible for the translation of unconventional self-antigen MPD6 in responsive to IFN-α stimulation. The eliciting anti-tumor immune response against unconventional antigen MPD6 in patients with myeloproliferative diseases indicates MPD6 as a target of novel immunotherapy. | 06-03-2010 |
20100036395 | METHOD AND APPARATUS OF ENDOSCOPIC SUTURING - An adjustable suture assembly is provided that may be employed in various surgical procedures to draw and/or hold tissue and/or muscle together. The suture assembly may include a suture lock or tensioner that is adjustably securable to two or more lengths of suture to provide a surgeon with an ability to maintain tissue or muscle in one secured position and subsequently readjust the suture assembly to maintain the tissue or muscle in a different secured position. The suture assembly may include two or more sutures having an anchor attached to an end of each suture for anchoring the suture to desired tissue or muscle. An endoscopic suturing device is provided to deliver and place two or more sutures in tissue or muscle during a surgical procedure. The suturing device may be configured to carry a plurality of sutures so that multiple sutures can be placed in tissue or muscle during a single intubation of the device. The suture assembly and suturing device may be employed with an endoscope to facilitate surgical treatment of obesity which involves narrowing and/or disabling the pyloric sphincter to reduce the rate of gastric emptying. | 02-11-2010 |
20100028368 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to formula (I): wherein Ar | 02-04-2010 |
20100024783 | ELECTRIC-FIELD ASSISTED FUEL ATOMIZATION SYSTEM AND METHODS OF USE - An apparatus ( | 02-04-2010 |
20100012122 | OPEN-CIRCUIT LIQUID VENTILATOR - An open-circuit liquid ventilation system includes a reservoir containing a breathable liquid, a patient interface receiving breathable liquid from the reservoir, a pump directing breathable liquid from the reservoir to the patient, a controller for the pump, and a tank for storing used breathable liquid. The system may be passive regarding expired liquid. Alternatively, the system may be active and include a bypass line connected to the pump such that used breathable liquid is drawn from the patient. The patient interface may be adapted to interface a gas ventilation system to facilitate a rapid conversion from gas to liquid ventilation. The system may include sensors monitoring pressure and volume parameters and may include an output displaying information including schematics and real time tracings regarding a ventilation procedure. | 01-21-2010 |
20090304736 | NOVEL TUMOR ANTIGENS ELICIT ANTI-TUMOR HUMORAL IMMUNE REACTIONS IN A SUBSET OF PATIENTS WITH POLYCYTHEMIA VERA - The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′untranslated region (3′UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy. | 12-10-2009 |
20090281066 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones - Methods of treating cancer using compounds according to Formula (I) are disclosed herein, wherein X, X | 11-12-2009 |
20090275650 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof - Compounds of Formula I: | 11-05-2009 |
20090191193 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof - Compounds useful as antiproliferative agents, including, for example, anticancer agents, according to formula I: | 07-30-2009 |
20090138979 | MANIPULATING SP1 ACTIVITY TO IMPROVE THERAPEUTIC CLONING - The observed over-expression of Sp1 target genes has inspired inventors to formulate a specific strategy for correcting many gene expression defects, and thus improve clone development. The invention is based on the belief that manipulating Sp1 activity can improve cloning. Inventors believe that cloning is inefficient in large part because of the continued expression of Sp1 target genes in the early cloned embryos, which causes clones to be very unlike normal embryos, and so makes them very unhealthy. Inventors propose that if over-expression of Sp1 target genes is prevented in early stage clones, this would greatly improve cloning efficiency by making the cloned embryos healthy again. | 05-28-2009 |
20090124828 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis - α,β-Unsaturated sulfides, sulfones, sulfoxides and sulfonamides according to Formula I: | 05-14-2009 |